Loading
Drugs approved on early signs of benefit are paid for as if they had proved they extend life. Pay a provisional price and adjust it, up or down, when the survival data come in.
Most accelerated oncology approvals rest on response rate or progression-free survival, and a substantial share later fail to show survival benefit, yet prices are set at launch and rarely fall. Coverage-with-evidence-development schemes exist (the UK Cancer Drugs Fund, Germany's post-launch benefit reassessment) but price adjustment is negotiated rather than automatic. The proposal is a contractual price schedule fixed at launch: a provisional price, a higher price if the confirmatory trial shows survival benefit above a threshold, a sharply lower price or rebate if it does not, with the payer co-funding registry follow-up.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value.
Shares Accelerated approval, Regulatory divergence between regions, Overall survival (OS).
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value.
Shares Regulatory divergence between regions, Prices and value.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value.